Loading
Latest filing published 18 Nov 2025 for Newbury Pharmaceuticals AB, €3,741. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Alsakali Equity AB is a declared insider of Newbury Pharmaceuticals AB, with filings sourced from Finansinspektionen. In total, 2 filings cover trades dated from 17 November 2025 to 18 November 2025.
Every open-market trade on record is a purchase: 2 purchases worth €12k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The newest entry dates from 18 November 2025: an open-market purchase of €3,741, in Newbury Pharmaceuticals AB. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations